Matthew Gantz, president and chief executive officer, Castle Creek Biosciences, discussed FCX-013 for the potential treatment of scleroderma.
Matthew Gantz
Advertisement
President and chief executive officer, Castle Creek Biosciences
Articles by Matthew Gantz
Matthew Gantz, president and chief executive officer, Castle Creek Biosciences, discussed the company and its pipeline.
Advertisement
Latest Updated Articles
Assessing Gene Therapy in Recessive Dystrophic Epidermolysis BullosaPublished: February 1st 2022 | Updated:
Targeting Unmet Needs in Rare Dermatologic Diseases With Gene TherapyPublished: February 18th 2022 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
FDA Activity Recap: November 2025 Features SMA Approval, Boxed Warning for Elevidys, and More
2
ImmunoLogic, Episode 7: "Turbocharging CAR T-Cells: The IL-9 Orthogonal Signal” With Anusha Kalbasi, MD
3
Karlla W. Brigatti, MS, CGC, on Accelerating SMA Diagnosis and Treatment
4
